Trends in survival of patients with primary plasma cell leukemia: a population based analysis
A partir des données des registres américains des cancers portant sur 445 patients atteints d'une leucémie primitive à plasmocytes entre 1973 et 2009, cette étude analyse l'évolution de la survie
Primary plasma cell leukemia (pPCL) is a rare malignancy with a very aggressive course and poor outcome. There has been significant improvement in the survival of multiple myeloma (MM) patients over the past decade as a result of the incorporation of autologous stem cell transplantation (ASCT) and novel agents in their treatment regimens. However, it is unknown whether these therapies have had a similar impact on the survival of patients with pPCL. We conducted an analysis of the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the trends in survival of 445 patients with pPCL over the time interval of 1973-2009. The widespread availability of ASCT and use of novel agents in the upfront setting of MM and pPCL began after 1995 and 2006, respectively. The median OS based on time periods of diagnosis were 5 months, 6 months, 4 months and 12 months for those diagnosed during 1973-1995, 1996-2000, 2001-2005 and 2006-2009 respectively (P = 0.001). Thus, the current study confirms the recent survival improvement in pPCL within a large US population which may be associated with the use of better therapeutic strategies.